ArcherDx and AstraZeneca to Develop Personalized Cancer Monitoring Assays
ArcherDx plans to leverage the personalized cancer monitoring assays to develop companion diagnostics for AstraZeneca’s associated immunooncology therapies.
Read MoreSearch Results for: lung cancer
Multicancer Blood Test, Combined with Imaging, Shows Promise as Screen for Cancer
The blood test followed by PET-CT imaging was 99.6% specific for cancer.
Read MoreArcherDx and Premier Partner to Deliver Personalized Genomic Testing
Stratafide genomic testing helps community hospitals deliver accurate and actionable genomic information to cancer patients and providers.
Read MoreBiocare Medical Launches Seven Antibody Markers for Clinical Diagnostic and Cancer Research Applications
The launch focuses on several immunooncology markers that are critical for early-stage cancer drug development and patient treatment.
Read More
Interventional Study to Evaluate Multicancer Early Detection Test
The Pathfinder study will enroll 6,200 participants to evaluate Grail’s investigational multicancer early detection test in clinical practice.
Read More